Qulipta

Qulipta (atogepant) is a once-daily oral pill made by AbbVie for the preventive treatment of migraines. It belongs to a newer class of migraine drugs called gepants — CGRP (calcitonin gene-related peptide) receptor antagonists that block a key pain-signaling molecule involved in migraines.

Without insurance, Qulipta can cost $800–$900 per month. AbbVie provides assistance programs for qualifying patients.

How to Afford Qulipta

• Uninsured patients who meet income requirements may receive Qulipta at no cost through myAbbVie Assist.
• Commercially insured patients can significantly reduce their monthly copay with the Qulipta Complete Savings Card.

ClariMeds will match you to the right free program for Qulipta and handle the application at no charge.

What Does Qulipta Treat?

Qulipta is FDA-approved for:

• Episodic migraine prevention in adults — for patients with up to 14 migraine days per month
• Chronic migraine prevention in adults — for patients with 15 or more headache days per month (at least 8 of which are migraines)

Qulipta is a preventive medication taken every day regardless of whether a migraine is occurring, not a treatment for acute migraine attacks in progress.

How Qulipta Works

CGRP is a neuropeptide released during migraine attacks that dilates blood vessels and transmits pain signals. Qulipta is a small molecule that binds to the CGRP receptor and blocks CGRP from docking — preventing the downstream cascade that leads to migraine pain. Because it is an oral pill (rather than a monthly injection like the anti-CGRP antibodies), Qulipta is particularly convenient for patients who prefer not to self-inject. Clinical trials showed Qulipta reduced monthly migraine days by up to 4–6 days compared to placebo.